nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—thyroid cancer—bone cancer	0.527	1	CtDrD
Vandetanib—EGFR—bone cancer	0.173	0.732	CbGaD
Vandetanib—CYP3A4—bone cancer	0.0633	0.268	CbGaD
Vandetanib—ABCC1—Epirubicin—bone cancer	0.0229	0.237	CbGbCtD
Vandetanib—ABCG2—Carboplatin—bone cancer	0.0142	0.147	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—bone cancer	0.0122	0.126	CbGbCtD
Vandetanib—ABCG2—Cisplatin—bone cancer	0.0122	0.126	CbGbCtD
Vandetanib—ABCC1—Methotrexate—bone cancer	0.0118	0.122	CbGbCtD
Vandetanib—ABCG2—Doxorubicin—bone cancer	0.00816	0.0844	CbGbCtD
Vandetanib—ABCG2—Methotrexate—bone cancer	0.0079	0.0818	CbGbCtD
Vandetanib—ALB—Methotrexate—bone cancer	0.00545	0.0564	CbGbCtD
Vandetanib—CYP3A4—Doxorubicin—bone cancer	0.00176	0.0182	CbGbCtD
Vandetanib—SRC—periosteum—bone cancer	0.00139	0.0709	CbGeAlD
Vandetanib—KDR—hindlimb—bone cancer	0.000913	0.0464	CbGeAlD
Vandetanib—ORM1—vertebral column—bone cancer	0.000863	0.0439	CbGeAlD
Vandetanib—KDR—appendage—bone cancer	0.000783	0.0398	CbGeAlD
Vandetanib—Erlotinib—NR1I2—bone cancer	0.000713	0.196	CrCbGaD
Vandetanib—Gefitinib—CHEK2—bone cancer	0.000605	0.166	CrCbGaD
Vandetanib—Bosutinib—CHEK2—bone cancer	0.000596	0.164	CrCbGaD
Vandetanib—Afatinib—EGFR—bone cancer	0.000547	0.15	CrCbGaD
Vandetanib—TYRO3—connective tissue—bone cancer	0.00044	0.0224	CbGeAlD
Vandetanib—LYN—connective tissue—bone cancer	0.000438	0.0223	CbGeAlD
Vandetanib—Erlotinib—EGFR—bone cancer	0.000386	0.106	CrCbGaD
Vandetanib—FLT3—connective tissue—bone cancer	0.000375	0.019	CbGeAlD
Vandetanib—RIPK2—connective tissue—bone cancer	0.000338	0.0172	CbGeAlD
Vandetanib—ERBB3—connective tissue—bone cancer	0.000324	0.0165	CbGeAlD
Vandetanib—PLK4—bone marrow—bone cancer	0.000312	0.0159	CbGeAlD
Vandetanib—RET—connective tissue—bone cancer	0.0003	0.0153	CbGeAlD
Vandetanib—AXL—connective tissue—bone cancer	0.000299	0.0152	CbGeAlD
Vandetanib—TYRO3—spinal cord—bone cancer	0.000292	0.0148	CbGeAlD
Vandetanib—EPHA5—spinal cord—bone cancer	0.000292	0.0148	CbGeAlD
Vandetanib—FYN—connective tissue—bone cancer	0.00028	0.0142	CbGeAlD
Vandetanib—TEK—connective tissue—bone cancer	0.000274	0.0139	CbGeAlD
Vandetanib—YES1—connective tissue—bone cancer	0.000253	0.0128	CbGeAlD
Vandetanib—STK35—tendon—bone cancer	0.000252	0.0128	CbGeAlD
Vandetanib—FLT3—bone marrow—bone cancer	0.000249	0.0127	CbGeAlD
Vandetanib—ABL2—tendon—bone cancer	0.000246	0.0125	CbGeAlD
Vandetanib—SRC—connective tissue—bone cancer	0.000243	0.0124	CbGeAlD
Vandetanib—Gefitinib—EGFR—bone cancer	0.000242	0.0664	CrCbGaD
Vandetanib—Bosutinib—EGFR—bone cancer	0.000238	0.0653	CrCbGaD
Vandetanib—RIPK2—tendon—bone cancer	0.000233	0.0118	CbGeAlD
Vandetanib—VEGFA—tendon—bone cancer	0.000232	0.0118	CbGeAlD
Vandetanib—FMO1—tendon—bone cancer	0.000231	0.0117	CbGeAlD
Vandetanib—IRAK4—tendon—bone cancer	0.000227	0.0115	CbGeAlD
Vandetanib—FLT4—bone marrow—bone cancer	0.000226	0.0115	CbGeAlD
Vandetanib—RIPK2—bone marrow—bone cancer	0.000225	0.0115	CbGeAlD
Vandetanib—VEGFA—bone marrow—bone cancer	0.000225	0.0114	CbGeAlD
Vandetanib—RIPK2—spinal cord—bone cancer	0.000224	0.0114	CbGeAlD
Vandetanib—VEGFA—spinal cord—bone cancer	0.000224	0.0114	CbGeAlD
Vandetanib—KDR—connective tissue—bone cancer	0.000224	0.0114	CbGeAlD
Vandetanib—IRAK4—bone marrow—bone cancer	0.00022	0.0112	CbGeAlD
Vandetanib—IRAK4—spinal cord—bone cancer	0.000219	0.0111	CbGeAlD
Vandetanib—PLK4—Idarubicin—Epirubicin—bone cancer	0.000216	0.115	CbGdCrCtD
Vandetanib—PLK4—Doxorubicin—Epirubicin—bone cancer	0.000216	0.115	CbGdCrCtD
Vandetanib—ERBB3—spinal cord—bone cancer	0.000215	0.0109	CbGeAlD
Vandetanib—RET—tendon—bone cancer	0.000206	0.0105	CbGeAlD
Vandetanib—FGR—tendon—bone cancer	0.000206	0.0105	CbGeAlD
Vandetanib—AXL—tendon—bone cancer	0.000206	0.0105	CbGeAlD
Vandetanib—MKNK1—bone marrow—bone cancer	0.000202	0.0103	CbGeAlD
Vandetanib—MKNK1—spinal cord—bone cancer	0.000202	0.0102	CbGeAlD
Vandetanib—LCK—bone marrow—bone cancer	0.0002	0.0102	CbGeAlD
Vandetanib—FGR—bone marrow—bone cancer	0.0002	0.0102	CbGeAlD
Vandetanib—PLK4—Epirubicin—Doxorubicin—bone cancer	0.0002	0.106	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Doxorubicin—bone cancer	0.0002	0.106	CbGdCrCtD
Vandetanib—RET—spinal cord—bone cancer	0.000199	0.0101	CbGeAlD
Vandetanib—AXL—spinal cord—bone cancer	0.000198	0.0101	CbGeAlD
Vandetanib—SLK—tendon—bone cancer	0.000198	0.0101	CbGeAlD
Vandetanib—PDGFRB—connective tissue—bone cancer	0.000194	0.00984	CbGeAlD
Vandetanib—FYN—tendon—bone cancer	0.000192	0.00979	CbGeAlD
Vandetanib—SLK—bone marrow—bone cancer	0.000192	0.00975	CbGeAlD
Vandetanib—SLK—spinal cord—bone cancer	0.000191	0.00971	CbGeAlD
Vandetanib—MAP4K5—tendon—bone cancer	0.000188	0.00956	CbGeAlD
Vandetanib—TEK—tendon—bone cancer	0.000188	0.00956	CbGeAlD
Vandetanib—FYN—bone marrow—bone cancer	0.000186	0.00948	CbGeAlD
Vandetanib—FYN—spinal cord—bone cancer	0.000186	0.00944	CbGeAlD
Vandetanib—MAP4K5—bone marrow—bone cancer	0.000182	0.00926	CbGeAlD
Vandetanib—ABL1—Doxorubicin—Epirubicin—bone cancer	0.000181	0.0966	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Epirubicin—bone cancer	0.000181	0.0966	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Epirubicin—bone cancer	0.000181	0.0966	CbGdCrCtD
Vandetanib—TEK—spinal cord—bone cancer	0.000181	0.00922	CbGeAlD
Vandetanib—MAP4K5—spinal cord—bone cancer	0.000181	0.00922	CbGeAlD
Vandetanib—EPHB6—tendon—bone cancer	0.00018	0.00914	CbGeAlD
Vandetanib—YES1—tendon—bone cancer	0.000174	0.00883	CbGeAlD
Vandetanib—EPHB6—spinal cord—bone cancer	0.000173	0.00881	CbGeAlD
Vandetanib—ABL1—connective tissue—bone cancer	0.000172	0.00877	CbGeAlD
Vandetanib—STK10—tendon—bone cancer	0.000172	0.00875	CbGeAlD
Vandetanib—YES1—bone marrow—bone cancer	0.000168	0.00855	CbGeAlD
Vandetanib—ABL1—Idarubicin—Doxorubicin—bone cancer	0.000168	0.0894	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—bone cancer	0.000168	0.0894	CbGdCrCtD
Vandetanib—ABL1—Epirubicin—Doxorubicin—bone cancer	0.000168	0.0894	CbGdCrCtD
Vandetanib—YES1—spinal cord—bone cancer	0.000167	0.00852	CbGeAlD
Vandetanib—STK10—bone marrow—bone cancer	0.000167	0.00848	CbGeAlD
Vandetanib—SRC—spinal cord—bone cancer	0.000161	0.00819	CbGeAlD
Vandetanib—KDR—tendon—bone cancer	0.000154	0.00782	CbGeAlD
Vandetanib—MAP2K5—tendon—bone cancer	0.000154	0.00782	CbGeAlD
Vandetanib—KDR—bone marrow—bone cancer	0.000149	0.00757	CbGeAlD
Vandetanib—MAP2K5—spinal cord—bone cancer	0.000148	0.00754	CbGeAlD
Vandetanib—KDR—spinal cord—bone cancer	0.000148	0.00754	CbGeAlD
Vandetanib—Erlotinib—CYP3A4—bone cancer	0.000141	0.0387	CrCbGaD
Vandetanib—PDGFRB—tendon—bone cancer	0.000133	0.00676	CbGeAlD
Vandetanib—PDGFRB—bone marrow—bone cancer	0.000129	0.00655	CbGeAlD
Vandetanib—PDGFRB—spinal cord—bone cancer	0.000128	0.00652	CbGeAlD
Vandetanib—ORM1—bone marrow—bone cancer	0.000121	0.00615	CbGeAlD
Vandetanib—ORM1—spinal cord—bone cancer	0.00012	0.00612	CbGeAlD
Vandetanib—ABL1—tendon—bone cancer	0.000119	0.00603	CbGeAlD
Vandetanib—ABL1—bone marrow—bone cancer	0.000115	0.00584	CbGeAlD
Vandetanib—ABL1—spinal cord—bone cancer	0.000114	0.00581	CbGeAlD
Vandetanib—Cardiac failure—Doxorubicin—bone cancer	9.22e-05	0.0021	CcSEcCtD
Vandetanib—Lethargy—Doxorubicin—bone cancer	9.18e-05	0.00209	CcSEcCtD
Vandetanib—Nervous system disorder—Cisplatin—bone cancer	9.13e-05	0.00208	CcSEcCtD
Vandetanib—Thrombocytopenia—Cisplatin—bone cancer	9.11e-05	0.00207	CcSEcCtD
Vandetanib—Blood creatinine increased—Epirubicin—bone cancer	9.11e-05	0.00207	CcSEcCtD
Vandetanib—Dehydration—Epirubicin—bone cancer	9.04e-05	0.00206	CcSEcCtD
Vandetanib—Skin disorder—Cisplatin—bone cancer	9.04e-05	0.00206	CcSEcCtD
Vandetanib—Hyponatraemia—Doxorubicin—bone cancer	9.03e-05	0.00205	CcSEcCtD
Vandetanib—ABCC1—tendon—bone cancer	9.03e-05	0.00459	CbGeAlD
Vandetanib—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	9e-05	0.00205	CcSEcCtD
Vandetanib—Dry skin—Epirubicin—bone cancer	8.91e-05	0.00203	CcSEcCtD
Vandetanib—Hypokalaemia—Epirubicin—bone cancer	8.85e-05	0.00201	CcSEcCtD
Vandetanib—Gefitinib—CYP3A4—bone cancer	8.83e-05	0.0242	CrCbGaD
Vandetanib—Pancreatitis—Methotrexate—bone cancer	8.8e-05	0.002	CcSEcCtD
Vandetanib—Bosutinib—CYP3A4—bone cancer	8.7e-05	0.0239	CrCbGaD
Vandetanib—Nasopharyngitis—Epirubicin—bone cancer	8.69e-05	0.00198	CcSEcCtD
Vandetanib—Gastritis—Epirubicin—bone cancer	8.6e-05	0.00196	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Epirubicin—bone cancer	8.58e-05	0.00195	CcSEcCtD
Vandetanib—Cardiac arrest—Doxorubicin—bone cancer	8.55e-05	0.00195	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Cisplatin—bone cancer	8.48e-05	0.00193	CcSEcCtD
Vandetanib—Blood creatinine increased—Doxorubicin—bone cancer	8.43e-05	0.00192	CcSEcCtD
Vandetanib—Dysphagia—Epirubicin—bone cancer	8.4e-05	0.00191	CcSEcCtD
Vandetanib—Influenza—Epirubicin—bone cancer	8.4e-05	0.00191	CcSEcCtD
Vandetanib—Dysuria—Methotrexate—bone cancer	8.4e-05	0.00191	CcSEcCtD
Vandetanib—Neutropenia—Methotrexate—bone cancer	8.4e-05	0.00191	CcSEcCtD
Vandetanib—Dehydration—Doxorubicin—bone cancer	8.37e-05	0.0019	CcSEcCtD
Vandetanib—Paraesthesia—Cisplatin—bone cancer	8.36e-05	0.0019	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Methotrexate—bone cancer	8.35e-05	0.0019	CcSEcCtD
Vandetanib—Dyspnoea—Cisplatin—bone cancer	8.3e-05	0.00189	CcSEcCtD
Vandetanib—Dry skin—Doxorubicin—bone cancer	8.25e-05	0.00188	CcSEcCtD
Vandetanib—Pancreatitis—Epirubicin—bone cancer	8.24e-05	0.00187	CcSEcCtD
Vandetanib—Photosensitivity reaction—Methotrexate—bone cancer	8.2e-05	0.00186	CcSEcCtD
Vandetanib—Hypokalaemia—Doxorubicin—bone cancer	8.19e-05	0.00186	CcSEcCtD
Vandetanib—Decreased appetite—Cisplatin—bone cancer	8.09e-05	0.00184	CcSEcCtD
Vandetanib—Bronchitis—Epirubicin—bone cancer	8.08e-05	0.00184	CcSEcCtD
Vandetanib—Pneumonia—Methotrexate—bone cancer	8.05e-05	0.00183	CcSEcCtD
Vandetanib—Nasopharyngitis—Doxorubicin—bone cancer	8.04e-05	0.00183	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Cisplatin—bone cancer	8.03e-05	0.00183	CcSEcCtD
Vandetanib—Infestation NOS—Methotrexate—bone cancer	8.01e-05	0.00182	CcSEcCtD
Vandetanib—Infestation—Methotrexate—bone cancer	8.01e-05	0.00182	CcSEcCtD
Vandetanib—Depression—Methotrexate—bone cancer	7.98e-05	0.00182	CcSEcCtD
Vandetanib—Gastritis—Doxorubicin—bone cancer	7.96e-05	0.00181	CcSEcCtD
Vandetanib—Pain—Cisplatin—bone cancer	7.96e-05	0.00181	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Methotrexate—bone cancer	7.94e-05	0.00181	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Doxorubicin—bone cancer	7.93e-05	0.0018	CcSEcCtD
Vandetanib—Renal failure—Methotrexate—bone cancer	7.87e-05	0.00179	CcSEcCtD
Vandetanib—Dysuria—Epirubicin—bone cancer	7.86e-05	0.00179	CcSEcCtD
Vandetanib—Neutropenia—Epirubicin—bone cancer	7.86e-05	0.00179	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Epirubicin—bone cancer	7.81e-05	0.00178	CcSEcCtD
Vandetanib—Stomatitis—Methotrexate—bone cancer	7.8e-05	0.00177	CcSEcCtD
Vandetanib—Conjunctivitis—Methotrexate—bone cancer	7.78e-05	0.00177	CcSEcCtD
Vandetanib—Dysphagia—Doxorubicin—bone cancer	7.78e-05	0.00177	CcSEcCtD
Vandetanib—Influenza—Doxorubicin—bone cancer	7.78e-05	0.00177	CcSEcCtD
Vandetanib—Pollakiuria—Epirubicin—bone cancer	7.76e-05	0.00177	CcSEcCtD
Vandetanib—Photosensitivity reaction—Epirubicin—bone cancer	7.67e-05	0.00174	CcSEcCtD
Vandetanib—Haematuria—Methotrexate—bone cancer	7.63e-05	0.00174	CcSEcCtD
Vandetanib—Pancreatitis—Doxorubicin—bone cancer	7.62e-05	0.00173	CcSEcCtD
Vandetanib—Weight decreased—Epirubicin—bone cancer	7.6e-05	0.00173	CcSEcCtD
Vandetanib—Hyperglycaemia—Epirubicin—bone cancer	7.58e-05	0.00172	CcSEcCtD
Vandetanib—Hepatobiliary disease—Methotrexate—bone cancer	7.57e-05	0.00172	CcSEcCtD
Vandetanib—Epistaxis—Methotrexate—bone cancer	7.55e-05	0.00172	CcSEcCtD
Vandetanib—Pneumonia—Epirubicin—bone cancer	7.54e-05	0.00171	CcSEcCtD
Vandetanib—Infestation NOS—Epirubicin—bone cancer	7.49e-05	0.0017	CcSEcCtD
Vandetanib—Infestation—Epirubicin—bone cancer	7.49e-05	0.0017	CcSEcCtD
Vandetanib—Bronchitis—Doxorubicin—bone cancer	7.48e-05	0.0017	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Epirubicin—bone cancer	7.43e-05	0.00169	CcSEcCtD
Vandetanib—Renal failure—Epirubicin—bone cancer	7.37e-05	0.00167	CcSEcCtD
Vandetanib—Body temperature increased—Cisplatin—bone cancer	7.36e-05	0.00167	CcSEcCtD
Vandetanib—Stomatitis—Epirubicin—bone cancer	7.3e-05	0.00166	CcSEcCtD
Vandetanib—Conjunctivitis—Epirubicin—bone cancer	7.28e-05	0.00166	CcSEcCtD
Vandetanib—Urinary tract infection—Epirubicin—bone cancer	7.28e-05	0.00166	CcSEcCtD
Vandetanib—Neutropenia—Doxorubicin—bone cancer	7.27e-05	0.00165	CcSEcCtD
Vandetanib—Dysuria—Doxorubicin—bone cancer	7.27e-05	0.00165	CcSEcCtD
Vandetanib—ABCG2—bone marrow—bone cancer	7.24e-05	0.00368	CbGeAlD
Vandetanib—Upper respiratory tract infection—Doxorubicin—bone cancer	7.23e-05	0.00164	CcSEcCtD
Vandetanib—Haemoglobin—Methotrexate—bone cancer	7.22e-05	0.00164	CcSEcCtD
Vandetanib—ABCG2—spinal cord—bone cancer	7.21e-05	0.00367	CbGeAlD
Vandetanib—Haemorrhage—Methotrexate—bone cancer	7.19e-05	0.00163	CcSEcCtD
Vandetanib—Pollakiuria—Doxorubicin—bone cancer	7.18e-05	0.00163	CcSEcCtD
Vandetanib—Haematuria—Epirubicin—bone cancer	7.14e-05	0.00162	CcSEcCtD
Vandetanib—Urinary tract disorder—Methotrexate—bone cancer	7.1e-05	0.00161	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—bone cancer	7.1e-05	0.00161	CcSEcCtD
Vandetanib—Hepatobiliary disease—Epirubicin—bone cancer	7.09e-05	0.00161	CcSEcCtD
Vandetanib—Epistaxis—Epirubicin—bone cancer	7.07e-05	0.00161	CcSEcCtD
Vandetanib—Urethral disorder—Methotrexate—bone cancer	7.05e-05	0.0016	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—bone cancer	7.03e-05	0.0016	CcSEcCtD
Vandetanib—Sinusitis—Epirubicin—bone cancer	7.03e-05	0.0016	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—bone cancer	7.01e-05	0.0016	CcSEcCtD
Vandetanib—Pneumonia—Doxorubicin—bone cancer	6.97e-05	0.00159	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—bone cancer	6.93e-05	0.00158	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—bone cancer	6.93e-05	0.00158	CcSEcCtD
Vandetanib—Visual impairment—Methotrexate—bone cancer	6.93e-05	0.00158	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—bone cancer	6.87e-05	0.00156	CcSEcCtD
Vandetanib—Bradycardia—Epirubicin—bone cancer	6.85e-05	0.00156	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—bone cancer	6.81e-05	0.00155	CcSEcCtD
Vandetanib—Erythema multiforme—Methotrexate—bone cancer	6.8e-05	0.00155	CcSEcCtD
Vandetanib—Haemoglobin—Epirubicin—bone cancer	6.76e-05	0.00154	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—bone cancer	6.76e-05	0.00154	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—bone cancer	6.74e-05	0.00153	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—bone cancer	6.74e-05	0.00153	CcSEcCtD
Vandetanib—Haemorrhage—Epirubicin—bone cancer	6.73e-05	0.00153	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—bone cancer	6.72e-05	0.00153	CcSEcCtD
Vandetanib—Asthenia—Cisplatin—bone cancer	6.68e-05	0.00152	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—bone cancer	6.67e-05	0.00152	CcSEcCtD
Vandetanib—Urinary tract disorder—Epirubicin—bone cancer	6.64e-05	0.00151	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—bone cancer	6.61e-05	0.0015	CcSEcCtD
Vandetanib—Urethral disorder—Epirubicin—bone cancer	6.59e-05	0.0015	CcSEcCtD
Vandetanib—Hepatobiliary disease—Doxorubicin—bone cancer	6.56e-05	0.00149	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—bone cancer	6.54e-05	0.00149	CcSEcCtD
Vandetanib—Angiopathy—Methotrexate—bone cancer	6.52e-05	0.00148	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—bone cancer	6.5e-05	0.00148	CcSEcCtD
Vandetanib—Visual impairment—Epirubicin—bone cancer	6.48e-05	0.00147	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—bone cancer	6.48e-05	0.00147	CcSEcCtD
Vandetanib—Diarrhoea—Cisplatin—bone cancer	6.37e-05	0.00145	CcSEcCtD
Vandetanib—Erythema multiforme—Epirubicin—bone cancer	6.36e-05	0.00145	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—bone cancer	6.35e-05	0.00144	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—bone cancer	6.34e-05	0.00144	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—bone cancer	6.3e-05	0.00143	CcSEcCtD
Vandetanib—Eye disorder—Epirubicin—bone cancer	6.29e-05	0.00143	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—bone cancer	6.26e-05	0.00142	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—bone cancer	6.26e-05	0.00142	CcSEcCtD
Vandetanib—Cardiac disorder—Epirubicin—bone cancer	6.24e-05	0.00142	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—bone cancer	6.22e-05	0.00142	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—bone cancer	6.15e-05	0.0014	CcSEcCtD
Vandetanib—Dysgeusia—Methotrexate—bone cancer	6.13e-05	0.00139	CcSEcCtD
Vandetanib—Angiopathy—Epirubicin—bone cancer	6.1e-05	0.00139	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—bone cancer	6.1e-05	0.00139	CcSEcCtD
Vandetanib—Mediastinal disorder—Epirubicin—bone cancer	6.06e-05	0.00138	CcSEcCtD
Vandetanib—Arrhythmia—Epirubicin—bone cancer	6.01e-05	0.00137	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—bone cancer	6e-05	0.00136	CcSEcCtD
Vandetanib—Alopecia—Epirubicin—bone cancer	5.94e-05	0.00135	CcSEcCtD
Vandetanib—Vomiting—Cisplatin—bone cancer	5.92e-05	0.00135	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—bone cancer	5.9e-05	0.00134	CcSEcCtD
Vandetanib—Mental disorder—Epirubicin—bone cancer	5.89e-05	0.00134	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—bone cancer	5.88e-05	0.00134	CcSEcCtD
Vandetanib—Rash—Cisplatin—bone cancer	5.87e-05	0.00133	CcSEcCtD
Vandetanib—Dermatitis—Cisplatin—bone cancer	5.86e-05	0.00133	CcSEcCtD
Vandetanib—Malnutrition—Epirubicin—bone cancer	5.86e-05	0.00133	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—bone cancer	5.82e-05	0.00132	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—bone cancer	5.78e-05	0.00131	CcSEcCtD
Vandetanib—Dysgeusia—Epirubicin—bone cancer	5.73e-05	0.0013	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—bone cancer	5.65e-05	0.00128	CcSEcCtD
Vandetanib—Muscle spasms—Epirubicin—bone cancer	5.63e-05	0.00128	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—bone cancer	5.61e-05	0.00128	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—bone cancer	5.56e-05	0.00126	CcSEcCtD
Vandetanib—Nausea—Cisplatin—bone cancer	5.53e-05	0.00126	CcSEcCtD
Vandetanib—Vision blurred—Epirubicin—bone cancer	5.52e-05	0.00125	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—bone cancer	5.5e-05	0.00125	CcSEcCtD
Vandetanib—Cough—Methotrexate—bone cancer	5.46e-05	0.00124	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—bone cancer	5.45e-05	0.00124	CcSEcCtD
Vandetanib—Convulsion—Methotrexate—bone cancer	5.42e-05	0.00123	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—bone cancer	5.42e-05	0.00123	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—bone cancer	5.33e-05	0.00121	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—bone cancer	5.33e-05	0.00121	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—bone cancer	5.31e-05	0.00121	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	5.29e-05	0.0012	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—bone cancer	5.21e-05	0.00118	CcSEcCtD
Vandetanib—Loss of consciousness—Epirubicin—bone cancer	5.15e-05	0.00117	CcSEcCtD
Vandetanib—Cough—Epirubicin—bone cancer	5.11e-05	0.00116	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—bone cancer	5.11e-05	0.00116	CcSEcCtD
Vandetanib—Convulsion—Epirubicin—bone cancer	5.07e-05	0.00115	CcSEcCtD
Vandetanib—Infection—Methotrexate—bone cancer	5.07e-05	0.00115	CcSEcCtD
Vandetanib—Hypertension—Epirubicin—bone cancer	5.06e-05	0.00115	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—bone cancer	5.01e-05	0.00114	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—bone cancer	5e-05	0.00114	CcSEcCtD
Vandetanib—Chest pain—Epirubicin—bone cancer	4.98e-05	0.00113	CcSEcCtD
Vandetanib—Arthralgia—Epirubicin—bone cancer	4.98e-05	0.00113	CcSEcCtD
Vandetanib—Anxiety—Epirubicin—bone cancer	4.97e-05	0.00113	CcSEcCtD
Vandetanib—Skin disorder—Methotrexate—bone cancer	4.96e-05	0.00113	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	4.95e-05	0.00113	CcSEcCtD
Vandetanib—Dry mouth—Epirubicin—bone cancer	4.88e-05	0.00111	CcSEcCtD
Vandetanib—Oedema—Epirubicin—bone cancer	4.78e-05	0.00109	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—bone cancer	4.76e-05	0.00108	CcSEcCtD
Vandetanib—Infection—Epirubicin—bone cancer	4.75e-05	0.00108	CcSEcCtD
Vandetanib—Cough—Doxorubicin—bone cancer	4.73e-05	0.00108	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—bone cancer	4.69e-05	0.00107	CcSEcCtD
Vandetanib—Nervous system disorder—Epirubicin—bone cancer	4.69e-05	0.00107	CcSEcCtD
Vandetanib—Thrombocytopenia—Epirubicin—bone cancer	4.68e-05	0.00106	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—bone cancer	4.68e-05	0.00106	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methotrexate—bone cancer	4.65e-05	0.00106	CcSEcCtD
Vandetanib—Skin disorder—Epirubicin—bone cancer	4.64e-05	0.00106	CcSEcCtD
Vandetanib—Insomnia—Methotrexate—bone cancer	4.62e-05	0.00105	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—bone cancer	4.61e-05	0.00105	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—bone cancer	4.61e-05	0.00105	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—bone cancer	4.6e-05	0.00105	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—bone cancer	4.59e-05	0.00104	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	4.58e-05	0.00104	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—bone cancer	4.55e-05	0.00104	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—bone cancer	4.51e-05	0.00103	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—bone cancer	4.49e-05	0.00102	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—bone cancer	4.44e-05	0.00101	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—bone cancer	4.42e-05	0.00101	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Methotrexate—bone cancer	4.41e-05	0.001	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—bone cancer	4.4e-05	0.001	CcSEcCtD
Vandetanib—Infection—Doxorubicin—bone cancer	4.39e-05	0.000999	CcSEcCtD
Vandetanib—Pain—Methotrexate—bone cancer	4.37e-05	0.000993	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Epirubicin—bone cancer	4.35e-05	0.00099	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—bone cancer	4.34e-05	0.000986	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—bone cancer	4.33e-05	0.000985	CcSEcCtD
Vandetanib—Insomnia—Epirubicin—bone cancer	4.32e-05	0.000983	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—bone cancer	4.29e-05	0.000977	CcSEcCtD
Vandetanib—Paraesthesia—Epirubicin—bone cancer	4.29e-05	0.000976	CcSEcCtD
Vandetanib—Dyspnoea—Epirubicin—bone cancer	4.26e-05	0.000969	CcSEcCtD
Vandetanib—Dyspepsia—Epirubicin—bone cancer	4.21e-05	0.000957	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—bone cancer	4.18e-05	0.00095	CcSEcCtD
Vandetanib—Decreased appetite—Epirubicin—bone cancer	4.15e-05	0.000945	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Epirubicin—bone cancer	4.13e-05	0.000938	CcSEcCtD
Vandetanib—Fatigue—Epirubicin—bone cancer	4.12e-05	0.000937	CcSEcCtD
Vandetanib—Pain—Epirubicin—bone cancer	4.09e-05	0.000929	CcSEcCtD
Vandetanib—Constipation—Epirubicin—bone cancer	4.09e-05	0.000929	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—bone cancer	4.04e-05	0.000918	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—bone cancer	4.04e-05	0.000918	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—bone cancer	4.03e-05	0.000916	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—bone cancer	4e-05	0.000909	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—bone cancer	3.97e-05	0.000903	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—bone cancer	3.94e-05	0.000896	CcSEcCtD
Vandetanib—Gastrointestinal pain—Epirubicin—bone cancer	3.91e-05	0.000889	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—bone cancer	3.89e-05	0.000885	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—bone cancer	3.84e-05	0.000874	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—bone cancer	3.82e-05	0.000868	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—bone cancer	3.81e-05	0.000867	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—bone cancer	3.78e-05	0.00086	CcSEcCtD
Vandetanib—Pain—Doxorubicin—bone cancer	3.78e-05	0.00086	CcSEcCtD
Vandetanib—Abdominal pain—Epirubicin—bone cancer	3.78e-05	0.000859	CcSEcCtD
Vandetanib—Body temperature increased—Epirubicin—bone cancer	3.78e-05	0.000859	CcSEcCtD
Vandetanib—Asthenia—Methotrexate—bone cancer	3.66e-05	0.000833	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—bone cancer	3.62e-05	0.000822	CcSEcCtD
Vandetanib—Pruritus—Methotrexate—bone cancer	3.61e-05	0.000822	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—bone cancer	3.5e-05	0.000795	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—bone cancer	3.5e-05	0.000795	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—bone cancer	3.49e-05	0.000795	CcSEcCtD
Vandetanib—Asthenia—Epirubicin—bone cancer	3.43e-05	0.00078	CcSEcCtD
Vandetanib—Pruritus—Epirubicin—bone cancer	3.38e-05	0.000769	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—bone cancer	3.38e-05	0.000768	CcSEcCtD
Vandetanib—Diarrhoea—Epirubicin—bone cancer	3.27e-05	0.000744	CcSEcCtD
Vandetanib—Vomiting—Methotrexate—bone cancer	3.25e-05	0.000738	CcSEcCtD
Vandetanib—Rash—Methotrexate—bone cancer	3.22e-05	0.000732	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—bone cancer	3.22e-05	0.000732	CcSEcCtD
Vandetanib—Headache—Methotrexate—bone cancer	3.2e-05	0.000727	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—bone cancer	3.17e-05	0.000721	CcSEcCtD
Vandetanib—Dizziness—Epirubicin—bone cancer	3.16e-05	0.000719	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—bone cancer	3.13e-05	0.000711	CcSEcCtD
Vandetanib—Vomiting—Epirubicin—bone cancer	3.04e-05	0.000691	CcSEcCtD
Vandetanib—Nausea—Methotrexate—bone cancer	3.03e-05	0.00069	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—bone cancer	3.03e-05	0.000688	CcSEcCtD
Vandetanib—Rash—Epirubicin—bone cancer	3.01e-05	0.000685	CcSEcCtD
Vandetanib—Dermatitis—Epirubicin—bone cancer	3.01e-05	0.000685	CcSEcCtD
Vandetanib—Headache—Epirubicin—bone cancer	2.99e-05	0.000681	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—bone cancer	2.92e-05	0.000665	CcSEcCtD
Vandetanib—Nausea—Epirubicin—bone cancer	2.84e-05	0.000646	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—bone cancer	2.81e-05	0.000639	CcSEcCtD
Vandetanib—Rash—Doxorubicin—bone cancer	2.79e-05	0.000634	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—bone cancer	2.79e-05	0.000633	CcSEcCtD
Vandetanib—Headache—Doxorubicin—bone cancer	2.77e-05	0.00063	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—bone cancer	2.63e-05	0.000597	CcSEcCtD
Vandetanib—ABCG2—Metabolism—GNA11—bone cancer	5.03e-06	7.1e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ATF1—bone cancer	5.03e-06	7.1e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—JUN—bone cancer	5.01e-06	7.08e-05	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—TP53—bone cancer	5.01e-06	7.07e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—TGFBR2—bone cancer	4.98e-06	7.04e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—MDM2—bone cancer	4.98e-06	7.04e-05	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—PTGS2—bone cancer	4.94e-06	6.99e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—JUN—bone cancer	4.94e-06	6.99e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—JUN—bone cancer	4.94e-06	6.99e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—JUN—bone cancer	4.93e-06	6.96e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SMO—bone cancer	4.92e-06	6.96e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ATF1—bone cancer	4.92e-06	6.95e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL3—bone cancer	4.9e-06	6.93e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—KIT—bone cancer	4.85e-06	6.86e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ATF1—bone cancer	4.84e-06	6.85e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—MDM2—bone cancer	4.81e-06	6.8e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—MMP9—bone cancer	4.81e-06	6.8e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFBR2—bone cancer	4.8e-06	6.79e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—MDM2—bone cancer	4.8e-06	6.78e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL3—bone cancer	4.8e-06	6.78e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—MDM2—bone cancer	4.78e-06	6.76e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—MMP9—bone cancer	4.77e-06	6.74e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SMO—bone cancer	4.74e-06	6.7e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL3—bone cancer	4.72e-06	6.68e-05	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—TP53—bone cancer	4.71e-06	6.65e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—EGFR—bone cancer	4.69e-06	6.63e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—PTGS2—bone cancer	4.64e-06	6.56e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—MDM2—bone cancer	4.61e-06	6.51e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—EGFR—bone cancer	4.61e-06	6.51e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—MDM2—bone cancer	4.57e-06	6.47e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—BRAF—bone cancer	4.56e-06	6.45e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—CYP3A4—bone cancer	4.56e-06	6.44e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—PLAU—bone cancer	4.55e-06	6.43e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—EGFR—bone cancer	4.53e-06	6.4e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—JUN—bone cancer	4.53e-06	6.4e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—EGFR—bone cancer	4.51e-06	6.37e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—GNA11—bone cancer	4.5e-06	6.36e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—EGFR—bone cancer	4.47e-06	6.31e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—EGFR—bone cancer	4.46e-06	6.31e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—KIT—bone cancer	4.44e-06	6.27e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—GSTP1—bone cancer	4.43e-06	6.26e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—KIT—bone cancer	4.42e-06	6.25e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NT5C3A—bone cancer	4.41e-06	6.23e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—GNA11—bone cancer	4.34e-06	6.13e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—KIT—bone cancer	4.33e-06	6.12e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—JUN—bone cancer	4.33e-06	6.12e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—KIT—bone cancer	4.32e-06	6.11e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—KIT—bone cancer	4.31e-06	6.09e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—TP53—bone cancer	4.3e-06	6.08e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—KIT—bone cancer	4.28e-06	6.05e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—KIT—bone cancer	4.26e-06	6.03e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFBR2—bone cancer	4.25e-06	6.01e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—MDM2—bone cancer	4.25e-06	6.01e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SMO—bone cancer	4.2e-06	5.93e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFBR2—bone cancer	4.19e-06	5.92e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ATF1—bone cancer	4.18e-06	5.91e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—JUN—bone cancer	4.17e-06	5.9e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—BRAF—bone cancer	4.17e-06	5.9e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFBR2—bone cancer	4.1e-06	5.8e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—EGFR—bone cancer	4.09e-06	5.78e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—KIT—bone cancer	4.08e-06	5.77e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL3—bone cancer	4.08e-06	5.77e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—MDM2—bone cancer	4.08e-06	5.77e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—MMP9—bone cancer	4.07e-06	5.75e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—BRAF—bone cancer	4.07e-06	5.75e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFBR2—bone cancer	4.04e-06	5.71e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—EGFR—bone cancer	4.04e-06	5.71e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ATF1—bone cancer	4.03e-06	5.7e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—BRAF—bone cancer	4.02e-06	5.68e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—EGFR—bone cancer	4e-06	5.66e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—EGFR—bone cancer	3.98e-06	5.63e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—JUN—bone cancer	3.98e-06	5.62e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IGF1R—bone cancer	3.94e-06	5.57e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—EGFR—bone cancer	3.94e-06	5.57e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—TP53—bone cancer	3.94e-06	5.56e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—KIT—bone cancer	3.94e-06	5.56e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL3—bone cancer	3.93e-06	5.56e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—EGFR—bone cancer	3.92e-06	5.55e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—GSTP1—bone cancer	3.9e-06	5.51e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KIT—bone cancer	3.89e-06	5.49e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—EGFR—bone cancer	3.89e-06	5.49e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—EGFR—bone cancer	3.89e-06	5.49e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—EGFR—bone cancer	3.87e-06	5.47e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IGF1R—bone cancer	3.86e-06	5.46e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—EGFR—bone cancer	3.84e-06	5.43e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—GNA11—bone cancer	3.84e-06	5.43e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—BRAF—bone cancer	3.84e-06	5.43e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MDM2—bone cancer	3.82e-06	5.4e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IGF1R—bone cancer	3.8e-06	5.37e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—EGFR—bone cancer	3.78e-06	5.35e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KIT—bone cancer	3.76e-06	5.31e-05	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—TP53—bone cancer	3.73e-06	5.28e-05	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—TP53—bone cancer	3.71e-06	5.25e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—BRAF—bone cancer	3.7e-06	5.23e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—JUN—bone cancer	3.69e-06	5.22e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KIT—bone cancer	3.68e-06	5.21e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—TP53—bone cancer	3.67e-06	5.19e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—BRAF—bone cancer	3.65e-06	5.16e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KIT—bone cancer	3.61e-06	5.1e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ENO2—bone cancer	3.58e-06	5.06e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ATF1—bone cancer	3.57e-06	5.05e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—EGFR—bone cancer	3.56e-06	5.03e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—KIT—bone cancer	3.55e-06	5.02e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—BRAF—bone cancer	3.53e-06	4.99e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MDM2—bone cancer	3.5e-06	4.94e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFBR2—bone cancer	3.49e-06	4.93e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—MDM2—bone cancer	3.48e-06	4.92e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL3—bone cancer	3.48e-06	4.92e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—MDM2—bone cancer	3.41e-06	4.82e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MDM2—bone cancer	3.41e-06	4.81e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—KIT—bone cancer	3.4e-06	4.81e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—MDM2—bone cancer	3.39e-06	4.8e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—BRAF—bone cancer	3.39e-06	4.79e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MDM2—bone cancer	3.37e-06	4.76e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFBR2—bone cancer	3.36e-06	4.75e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—MDM2—bone cancer	3.36e-06	4.75e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—JUN—bone cancer	3.32e-06	4.69e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—DHFR—bone cancer	3.32e-06	4.69e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—EGFR—bone cancer	3.29e-06	4.65e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—EGFR—bone cancer	3.29e-06	4.65e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IGF1R—bone cancer	3.28e-06	4.64e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—EGFR—bone cancer	3.28e-06	4.64e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—KIT—bone cancer	3.28e-06	4.63e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TP53—bone cancer	3.26e-06	4.61e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MMP9—bone cancer	3.23e-06	4.57e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MDM2—bone cancer	3.22e-06	4.55e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—BRAF—bone cancer	3.2e-06	4.52e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF1R—bone cancer	3.16e-06	4.47e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—EGFR—bone cancer	3.15e-06	4.45e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—KIT—bone cancer	3.14e-06	4.44e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—EGFR—bone cancer	3.13e-06	4.42e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GNA11—bone cancer	3.1e-06	4.38e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PTGS2—bone cancer	3.1e-06	4.38e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—MDM2—bone cancer	3.1e-06	4.38e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—BRAF—bone cancer	3.08e-06	4.35e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MDM2—bone cancer	3.06e-06	4.33e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TP53—bone cancer	3.06e-06	4.32e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—JUN—bone cancer	3.04e-06	4.29e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—JUN—bone cancer	3.03e-06	4.28e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—PTGS2—bone cancer	2.99e-06	4.22e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFBR2—bone cancer	2.98e-06	4.21e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—JUN—bone cancer	2.96e-06	4.19e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—JUN—bone cancer	2.96e-06	4.18e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MDM2—bone cancer	2.96e-06	4.18e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MMP9—bone cancer	2.96e-06	4.18e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—JUN—bone cancer	2.95e-06	4.17e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—JUN—bone cancer	2.93e-06	4.14e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—JUN—bone cancer	2.92e-06	4.13e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—EGFR—bone cancer	2.9e-06	4.1e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—KIT—bone cancer	2.9e-06	4.1e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MDM2—bone cancer	2.9e-06	4.1e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MMP9—bone cancer	2.88e-06	4.07e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KIT—bone cancer	2.86e-06	4.04e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MMP9—bone cancer	2.85e-06	4.03e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MDM2—bone cancer	2.84e-06	4.02e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CYP3A4—bone cancer	2.81e-06	3.97e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF1R—bone cancer	2.8e-06	3.96e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KIT—bone cancer	2.8e-06	3.96e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.8e-06	3.95e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—MDM2—bone cancer	2.8e-06	3.95e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—EGFR—bone cancer	2.79e-06	3.94e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KIT—bone cancer	2.76e-06	3.9e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTGS2—bone cancer	2.74e-06	3.87e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—BRAF—bone cancer	2.73e-06	3.85e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—bone cancer	2.71e-06	3.83e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—BRAF—bone cancer	2.69e-06	3.8e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—MDM2—bone cancer	2.68e-06	3.79e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—JUN—bone cancer	2.66e-06	3.76e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—BRAF—bone cancer	2.63e-06	3.72e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—EGFR—bone cancer	2.61e-06	3.69e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—BRAF—bone cancer	2.59e-06	3.66e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MMP9—bone cancer	2.59e-06	3.66e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTGS2—bone cancer	2.58e-06	3.65e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—MDM2—bone cancer	2.58e-06	3.65e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—JUN—bone cancer	2.57e-06	3.63e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—JUN—bone cancer	2.52e-06	3.56e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MMP9—bone cancer	2.5e-06	3.53e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTGS2—bone cancer	2.49e-06	3.52e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—MDM2—bone cancer	2.47e-06	3.5e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—JUN—bone cancer	2.43e-06	3.43e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GSTP1—bone cancer	2.4e-06	3.4e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—EGFR—bone cancer	2.39e-06	3.38e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KIT—bone cancer	2.38e-06	3.37e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—EGFR—bone cancer	2.38e-06	3.36e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—EGFR—bone cancer	2.33e-06	3.29e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EGFR—bone cancer	2.33e-06	3.29e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—EGFR—bone cancer	2.32e-06	3.28e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EGFR—bone cancer	2.3e-06	3.25e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KIT—bone cancer	2.3e-06	3.24e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—EGFR—bone cancer	2.29e-06	3.24e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—bone cancer	2.29e-06	3.24e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—MDM2—bone cancer	2.28e-06	3.23e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MDM2—bone cancer	2.25e-06	3.18e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—BRAF—bone cancer	2.24e-06	3.16e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MDM2—bone cancer	2.21e-06	3.12e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—bone cancer	2.2e-06	3.11e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—EGFR—bone cancer	2.2e-06	3.11e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—bone cancer	2.19e-06	3.1e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MDM2—bone cancer	2.17e-06	3.07e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—BRAF—bone cancer	2.16e-06	3.05e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—JUN—bone cancer	2.15e-06	3.04e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—EGFR—bone cancer	2.12e-06	2.99e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EGFR—bone cancer	2.09e-06	2.96e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KIT—bone cancer	2.03e-06	2.87e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EGFR—bone cancer	2.02e-06	2.86e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—bone cancer	2.02e-06	2.85e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—bone cancer	2.01e-06	2.83e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—JUN—bone cancer	1.96e-06	2.77e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—bone cancer	1.95e-06	2.76e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EGFR—bone cancer	1.94e-06	2.74e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—bone cancer	1.93e-06	2.73e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ENO2—bone cancer	1.93e-06	2.73e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—JUN—bone cancer	1.92e-06	2.71e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—EGFR—bone cancer	1.91e-06	2.7e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—BRAF—bone cancer	1.91e-06	2.7e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—bone cancer	1.9e-06	2.69e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—JUN—bone cancer	1.89e-06	2.67e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MDM2—bone cancer	1.88e-06	2.65e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—bone cancer	1.86e-06	2.64e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—bone cancer	1.84e-06	2.59e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—bone cancer	1.83e-06	2.58e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MDM2—bone cancer	1.81e-06	2.55e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—DHFR—bone cancer	1.79e-06	2.53e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—bone cancer	1.76e-06	2.49e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—bone cancer	1.76e-06	2.48e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—bone cancer	1.7e-06	2.4e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—bone cancer	1.69e-06	2.39e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GNA11—bone cancer	1.67e-06	2.37e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—JUN—bone cancer	1.63e-06	2.3e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MDM2—bone cancer	1.6e-06	2.26e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—bone cancer	1.59e-06	2.24e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—JUN—bone cancer	1.57e-06	2.22e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—bone cancer	1.56e-06	2.21e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—bone cancer	1.54e-06	2.18e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—bone cancer	1.53e-06	2.16e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—bone cancer	1.51e-06	2.13e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—bone cancer	1.48e-06	2.1e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—JUN—bone cancer	1.39e-06	1.97e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—bone cancer	1.35e-06	1.91e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTP1—bone cancer	1.3e-06	1.83e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—bone cancer	1.29e-06	1.83e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—bone cancer	1.27e-06	1.79e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—bone cancer	1.25e-06	1.76e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—bone cancer	1.25e-06	1.76e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—bone cancer	1.24e-06	1.75e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—bone cancer	1.09e-06	1.55e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—bone cancer	1.08e-06	1.52e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—bone cancer	1.04e-06	1.47e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—bone cancer	9.18e-07	1.3e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—bone cancer	6.72e-07	9.5e-06	CbGpPWpGaD
